Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.

In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.

The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.